H. Jack West, MD

Articles

Final Thoughts on Effective Therapy and Financial Toxicity

September 20th 2021

Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.

Innovation of Therapies vs Disruptive Pricing

September 20th 2021

A panel of experts debate the cost of innovation vs disruptive pricing of therapy.

Mitigating Strategies Appropriate for EGFR Therapy and Financial Toxicity

September 13th 2021

Jack West, MD, and Gilberto Lopes, MD, share their thoughts on mitigating strategies of therapy associated with financial toxicity.

Review of GEMSTONE-301 and -302 Data

September 13th 2021

Mark Socinski, MD, and Jack West, MD, review the GEMSTONE-301 and GEMSTONE-302 trials.

Significance of PD-L1/PD-1 Testing in NSCLC

September 7th 2021

A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.

Pharmacoeconomic Considerations for Immunotherapy

September 7th 2021

Gilberto Lopes, MD, Jack West, MD, and Mark Socinski, MD, provide their insight on the pharmacoeconomic considerations for immunotherapy.

Impact of Immunotherapy on Standard of Care for NSCLC and GI Cancers

August 30th 2021

Experts in cancer care management review PD-1/PD-L1 immunotherapy for patients with NSCLC and GI cancers.

Place for EGFR Agents and Comparison of Costs

August 30th 2021

A panel of experts discuss treatment options based on efficacy and out-of-pocket cost for patients.

Dr. West on the Use of Nivolumab/Ipilimumab in Metastatic NSCLC

January 14th 2021

Howard (Jack) West, MD, discusses the use of nivolumab in combination with ipilimumab in metastatic non–small cell lung cancer.

Dr. West on FDA Approval of Lorlatinib in ALK+ NSCLC

November 3rd 2018

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of lorlatinib for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).

Dr. West Discusses Latest Immunotherapy Findings in Lung Cancer

July 17th 2018

H. Jack West, MD, medical director of thoracic oncology, Swedish Cancer Institute of Swedish Medical Center, discusses the latest immunotherapy findings for lung cancer treatment.

Dr. West on FDA Approval of Frontline Osimertinib in EGFR+ NSCLC

April 19th 2018

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutation

Dr. West on FDA Approval of Afatinib in NSCLC With Rare EGFR Mutations

January 15th 2018

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of afatinib (Gilotrif) for the frontline treatment of patients with metastatic non

Dr. West Discusses Chemotherapy Without Driver Mutations in NSCLC

January 11th 2018

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute at Swedish Medical Center, discusses chemotherapy in patients with non

Treating Advanced Non-Driver Lung Adenocarcinoma

November 11th 2017

The approach to first-line treatment of advanced non-small cell lung cancer (NSCLC) has been evolving rapidly, particularly with respect to patients with lung adenocarcinoma.

Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC

November 7th 2017

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of alectinib (Alecensa) as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).

Dr. West on Lurbinectedin in SCLC

September 20th 2017

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the emerging agent lurbinectedin in the small cell lung cancer (SCLC) landscape.

Dr. West on the Significance of the PACIFIC Trial in NSCLC

September 13th 2017

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the significance of the PACIFIC trial in patients with non

Dr. West on Emerging Changes in the Field of EGFR-Mutant NSCLC

June 6th 2017

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses some potential emerging changes coming to the field of EGFR-mutant non–small cell lung cancer (NSCLC), including next-generation EGFR inhibitors such as osimertinib (Tagrisso) that is now being explored in the FLAURA trial as a frontline treatment for these patients.

Dr. West on FDA Approval of Frontline Ceritinib for Frontline ALK+ NSCLC

May 27th 2017

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of ceritinib (Zykadia) as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).